Filing Flows › Comparisons › VNRX vs CLDX
Volitionrx vs Celldex Therapeutics: VNRX and CLDX compared
Volitionrx is the larger company: $399K of revenue in its latest quarter (Q2 2026) against $22K for Celldex Therapeutics (Q2 2026). Volitionrx is growing faster (-2% against -97% a year earlier).
Where the money goes: VNRX and CLDX
Volitionrx (VNRX) · Q2 2026
Volitionrx, Q2 2026: revenue $399K (-2% year over year), net loss $7.3M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
Celldex Therapeutics (CLDX) · Q2 2026
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
| Volitionrx (VNRX) | Celldex Therapeutics (CLDX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $399K | $22K |
| Revenue growth, Y/Y | -2% | -97% |
| Operating margin | n/m | n/m |
| Net earnings | −$7.3M | −$73.5M |
| Operating cash flow | −$5.2M | −$57.4M |
Where the revenue comes from
Celldex Therapeutics
- Contracts and grants: $15K (68%)
- Product development and licensing agreements: $7K (32%)
Questions
Which is bigger, Volitionrx or Celldex Therapeutics?
Volitionrx is the larger company: $399K of revenue in its latest quarter (Q2 2026) against $22K for Celldex Therapeutics (Q2 2026).
Is Volitionrx or Celldex Therapeutics growing faster?
Volitionrx is growing faster (-2% against -97% a year earlier).
More: Volitionrx earnings · how Volitionrx makes money · Celldex Therapeutics earnings · how Celldex Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.